Overview

Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder

Status:
Recruiting
Trial end date:
2022-04-27
Target enrollment:
Participant gender:
Summary
Placebo-controlled study to evaluate the efficacy and safety of oral ACT-539313 in the treatment of adults with moderate to severe binge eating disorder
Phase:
Phase 2
Details
Lead Sponsor:
Idorsia Pharmaceuticals Ltd.